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I. Summary 31 
Background: Human respiratory syncytial virus (HRSV) is a leading viral etiologic agent of 32 
pediatric lower respiratory infections, including bronchiolitis and pneumonia. There are two 33 
antigenic subgroups, HRSV A and B, each containing several genotypes. While viral load 34 
may vary among HRSV genotypes and affect the clinical course of disease, data are scarce 35 
regarding the actual differences of viral load among genotypes. While, there are several 36 
studies on HRSV viral load association with disease severity using different disease models, 37 
investigations of HRSV viral load association with clinical diagnosed disease severity are 38 
limited. Therefore, I conducted these studies to estimate and compare viral load among HRSV 39 
genotypes particularly between NA1 and ON1 genotypes of HRSV A. ON1 is a newly 40 
emerged genotype with a 72-nucleotide duplication in the G gene. Also, this aimed to 41 
determine the relationship of HRSV viral load with clinical diagnosed disease severity.  42 
Methods: Hospitalized children aged less than 5 years with severe acute respiratory illness 43 
between September 2012 and December 2013 were recruited for comparison of viral load 44 
among HRSV genotypes. In 2014, patients with initial diagnosis of acute respiratory 45 
infections including non-pneumonia, pneumonia, severe or very severe pneumonia (SP / VSP) 46 
who either visited rural health units (RHUs) or hospitalized in 2014 were also recruited in the 47 
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study to determine relationship between HRSV viral load and disease severity. Clinical 48 
diagnosis of pneumonia, SP and VSP were based on IMCI (Integrated management of 49 
childhood illness) guidelines. Quantitative PCR (qPCR) was used to measure HRSV viral 50 
load in nasopharyngeal swab.  51 
Results: The viral load of NA1 was significantly higher than those of ON1 and BA in 139 52 
samples analyzed. Regression analysis showed that both genotype NA1 and younger age were 53 
significantly associated with high HRSV viral load. In 2014, a total of 267 children were 54 
analyzed for association between virus load and disease severity. Their initial diagnosis were 55 
classified as non-pneumonia in 72 episodes (26.7%), pneumonia in 67 (24.8%) and SP / VSP 56 
in 131 (48.5%). The non-pneumonia group had a shorter median day (3 days) of number of 57 
sick days before sampling than pneumonia (4 days) or SP / VSP (4 days) (P = .006). In 58 
multivariate analysis, disease severity lost association while patient facility and duration of 59 
illness prior to sampling remained significantly associated with HRSV viral load.   60 
Conclusion: The viral load of NA1 was higher than those of ON1 and BA9. HRSV genotypes 61 
may be associated with HRSV viral load. Age was found to be a potential predictor of HRSV 62 
viral load.  HRSV viral load was significantly higher in younger age group than older age 63 
group. Patient facilities were also associated with viral load, i.e. patients visiting RHUs had 64 
 6 
higher viral load compared with hospitalized patients. Patients who visited RHUs had shorter 65 
duration of illness prior to sample collection than hospitalized patients. I found no association 66 
of clinical disease severity by IMCI criteria with HRSV viral load but the timing of the 67 
sampling strongly affected the viral load. The reasons and clinical impacts of these differences 68 
in viral load among HRSV genotypes require further evaluation. Prediction and evaluation of 69 
clinical severity based on IMCI guidelines may need more validation and improvement.   70 
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II. Introduction 71 
Human respiratory syncytial virus (HRSV) is a major etiologic agent of lower respiratory 72 
tract infections (LRTI) including bronchiolitis and pneumonia both in developing and 73 
developed countries 1-4. It is also a leading cause of hospitalizations among infants with 74 
severe symptoms 5. Most hospitalized cases were previously healthy children 6. HRSV is an 75 
enveloped non-segmented negative sense and single-stranded RNA virus in the Pneumovirus 76 
genus of the family of Paramyxoviridae. It carries 10 genes (Figure 1) and encodes 11 77 
proteins, since the M2 matrix gene presents two overlapping reading frames yielding two 78 
different M2-1 and M2-2 proteins.  79 
There is a single serotype of HRSV with 2 major antigenic subgroups HRSV-A and 80 
HRSV-B and several genotypes. Subgrouping is defined based on reactions with monoclonal 81 
antibodies against the G and F glycoproteins 7,8 and genetic differences 9. HRSV genotyping 82 
is based on the genetic variability of the G protein gene and there are currently several HRSV-83 
A and HRSV-B genotypes reported worldwide under different designations. In HRSV-A, there 84 
have been 11 genotypes reported. These include GA1 to GA7 10,11, SAA1 12, NA1 and NA2 13 85 
and most recently emerged ON1 (Ontario) with 72 nucleotide duplication in the G gene 14. 86 
For HRSV-B, there are currently 19 genotypes including GB1 to GB4 11, SAB1 to SAB3 12 87 
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and BA (Buenos Aires) genotype with 60 nucleotide duplication in G gene which are 88 
subdivided into BA1 to BA12 15-18. To date, there is no data yet on the comparison of HRSV 89 
viral load among genotypes, relevant for better comprehension of the impact of genotypes in 90 
the pathogenesis of HRSV and clinical course of HRSV disease. There are emerging 91 
genotypes with nucleotide duplication in the hypervariable region of the G gene for both 92 
HRSV-A and HRSV-B; BA genotype with 60 nucleotide duplication in HRSV-B replaced 93 
previous genotypes 15-18 and ON1 derived from NA1 genotype with 72-nucleotide duplication 94 
of HRSV-A is now detected in many regions in the world 14,18-28. Meanwhile, attention has not 95 
been given yet for potential difference in viral load among HRSV genotypes in pediatric 96 
patients. Potential difference in the pathogenesis of HRSV genotypes may demonstrate their 97 
important roles in HRSV pathogenesis and clinical disease course.  98 
HRSV viral load is an important factor in HRSV disease severity 6. Previous studies using 99 
various disease models showed high HRSV viral load to be a risk factor for severe disease 100 
using severity index, which include hospitalization, duration of hospitalization, requirement 101 
for intensive care 6,29-34. Criteria for hospital discharge or requirement for intensive care unit 102 
are varied across studies and those severity indexes as indicators may not always be adequate 103 
to replicate the study, especially in developing countries due to several factors such as health 104 
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seeking behavior, refusal of admission and self-discharge. While some studies on HRSV viral 105 
load and disease severity have been mainly carried out in hospital settings, one study included 106 
non-severe outpatient cases, where results showed lower viral load in outpatients than severe 107 
hospitalized patients, but the association was not constant throughout the age groups 34. 108 
Data on association of HRVS viral load with clinical disease severity is lacking.  109 
Relationship between HRSV viral load and clinical disease severity may demonstrate direct 110 
association and the relevance of viral load in HRSV disease and severity. Currently, data on 111 
HRSV studies in developing countries are limited and especially on HRSV pathogenesis. In 112 
this study, I compared the viral load of different genotypes of HRSV and determined the 113 
association of viral load with clinical disease severity. This study was conducted to 114 
understand better the impact of genotypes on HRSV viral load pathogenesis.  115 
 116 
  117 
 118 
 119 
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III. METHODS 122 
 123 
Patients and clinical samples 124 
Between September 2012 and December 2013, nasopharyngeal swabs (NPS) were collected 125 
from children aged < 5 years, who were admitted in Biliran Provincial Hospital (BPH) with 126 
severe acute respiratory infection. In the second year (2014), children who visited the two 127 
rural health units (RHUs) in Caibiran and Kawayan municipalities or admitted in BPH 128 
regardless of residential address were included in this study. RHUs are primary healthcare 129 
facilities located in each municipality to which a qualified physician is assigned to provide 130 
outpatient care. There are eight municipalities with one RHU each, and only one referral 131 
hospital of which 20 beds are allocated to the pediatric ward in Biliran Island (Figure 2) 35. 132 
For the hospital site, patients with acute respiratory illness were evaluated from January 133 
to December 2014 and those who had severe or very severe pneumonia according to the IMCI 134 
guidelines requiring hospitalization were recruited. From February to December 2014, 135 
patients who visited one of two RHUs with cough or cold were sampled and evaluated 136 
according to IMCI guidelines and enrolled. All cases were screened with the presence of fever, 137 
cough or difficulty of breathing as initial assessment. 138 
 11 
The guardian was interviewed to provide history of illness, the date of onset of individual 139 
clinical symptoms, which included fever, cough and breathing difficulty within the last 140 
fourteen days. If a child had > 14 days of chronic cough or without cough, the onset of 141 
disease was defined by fever or difficulty to breathe. The earliest of any of these symptoms 142 
from the date of onset to RHUs visit or hospital admission was used to define the duration of 143 
illness from the onset to the NPS sampling in the statistical analysis.  144 
The Institutional Review Boards of the Research Institute for Tropical Medicine (RITM) 145 
approved this study as well as the Ethics Committee of Tohoku University Graduate School of 146 
Medicine. Prior to enrollment of children in this study, informed consents were obtained from 147 
guardians. 148 
 149 
Nutritional status: Height for age 150 
Patient`s demographic and anthropometric information, including age, gender, height and 151 
length of subjects were taken. The nutritional status of subjects was assessed using the WHO 152 
anthro software 36 and Z-scores were determined. Based on Z-score results, subjects were 153 
classified as adequate (-2< Z-score<+2), moderately malnourished (-3< Z-score<-2), and 154 
severely malnourished (Z-score <-3) 37. 155 
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Pneumonia clinical diagnosis 156 
     A “pneumonia case” was defined based on symptoms assessed by the study nurse, 157 
including cough, fast breathing (60 or more breath/min for subjects aged < 2 months, 50 or 158 
more breath/min for subjects aged 2 months to 12 months, and 40 or more breath/min for 159 
subjects aged 12 months up to < 5 years), chest indrawing, inability to drink or suck, cyanosis, 160 
convulsions. Pneumonia was defined and classified using the IMCI guidelines 38. Cough and 161 
fast breathing were classified as pneumonia. Pneumonia accompanied with chest indrawing or 162 
inability to drink or suck, cyanosis, convulsions were classified as severe or very severe 163 
pneumonia. Patients with acute respiratory symptoms who did not meet the criteria for 164 
pneumonia were defined as “non-pneumonia”. 165 
 166 
Radiography 167 
Chest radiographs were taken at admission for subjects hospitalized in 2013 and 168 
interpretations were performed by an independent designated radiologist trained in the 169 
standard interpretation of chest radiographs for the diagnosis of childhood pneumonia as 170 
previously described 39. The presence or absence of infiltrate on X chest ray was analyzed for 171 
association with HRSV viral load. 172 
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Nasopharyngeal specimen collection 173 
All NPS samples were taken by trained staff at each site using EX-swab 002  174 
 (DENKA SEIKEN Tokyo) and kept at 0-4 °C. Samples are transferred from RHUs to 175 
hospital for shipment. Samples were stirred in 3ml viral transport medium, which consists of 176 
Hanks BSS (Balanced salt solution), 0.25% gelatin, 0.035% sodium bicarbonate, 177 
Streptomycin (500 μg/mL) and Penicillin (500 U/mL) and Amphotericin B (250 μg/mL) and 178 
transported twice a week from the hospital to Research Institute for Tropical Medicine 179 
(RITM) in Manila and processed for virological tests as soon as they arrived at RITM. 180 
 181 
Viral RNA Extraction, cDNA synthesis and qPCR 182 
QIAamp® MinElute® Virus Spin kit. (QIAGEN, Hilden, Germany) was used to extract viral 183 
RNA from the samples. M-MLV (Moloney murine leukemia virus) reverse transcriptase and 184 
random primers (Thermo Scientific, Boston, MA, USA) were used for complementary DNA 185 
(cDNA) synthesis. HRSV was screened by qPCR targeting a conserved region of N gene in 186 
both HRSV-A and HRSV-B as previously described with some modifications 40. Briefly, 187 
HRSV cDNA sequences were amplified and detected by qPCR on Applied Biosystems® 188 
StepOnePlus™. The reaction is composed of 300 nM forward primer 189 
 14 
(GCTCTTAGCAAAGTCAAGTTRAATGATACA), 300 nM reverse primer 190 
(GTTTYTGCACATCATAATTRGGAGT), 200 nM TaqMan probe VIC™ dye 191 
(CTRTCATCCAGCAAATAYACYATCCAACGKAGYACAGG) and 200 nM minor groove 192 
binder (MGB) non-fluorescent quencher (NFQ). 193 
 A volume of 1 μL of viral cDNA was added to make a final volume of 10 μL per reaction. 194 
The PCR thermal cycle condition was set at 95°C for 20 seconds, followed by 40 cycles of 195 
denaturation at 95°C for 1 second, annealing and elongation at 60 °C for 20 seconds. HRSV 196 
viral load measurement was carried out in duplicates. HRSV viral load was defined by the 197 
number of amplification cycles needed for a positive PCR test (cycle threshold, Ct value). Ct 198 
values provide a semi-quantitative measure of viral load, with a highly significant inverse 199 
linear relationship between viral load and Ct-values 41,42. Therefore, the lower the Ct-value, 200 
the higher the amount of viral material and vice versa. Measurement of reference standard 201 
was performed and a Ct value of 19 is approximately equivalent to 4.1 log TCID50/mL of 202 
infectious HRSV, while a Ct value of 33 is approximately 1 log TCID50/mL of infectious 203 
HRSV. The system detection limit was 10 copies/reaction using standard RNA with Ct of 38.2. 204 
Ct values > 38.2 and < 40 were considered positive if conventional PCR for genotyping was 205 
positive or amplification plot showed exponential fluorescence growth. 206 
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Also, subgrouping and genotyping were performed as previously described with some 207 
modification 43. Briefly, the C-terminus of the G gene, which includes the second 208 
hypervariable region (HRSV-A 270/342 nt, HRSV-B 270/330 nt) was amplified by nested 209 
PCR 44. After the purification of amplification products using illustra™ ExoProStar™, 210 
nucleotide sequence was determined using BigDye Terminator v1.1 Cycle Sequencing Kit 211 
and Genetic Analyzer 3730 (Thermo Scientific, Boston, MA, USA).  212 
For HRSV genotypes viral load, RNA copy number standard samples containing target region 213 
of Reverse transcriptase (RT)-qPCR, were synthesized for partial sequence (658 nucleotides) 214 
of genomic RNA of HRSV for genotypes NA1, ON1 and BA9 respectively, using T7 215 
RiboMAX (Promega). The synthesized RNA was treated with DNase and isolated using 216 
TRIzol (Thermo Fisher Scientific). Concentration of the standard RNA samples was 217 
measured using Nanodrop (Thermo Fisher Scientific) and converted to copy number based on 218 
their molecular weight. RT-qPCR was performed for the standard RNA samples as well as 219 
clinical samples, and equivalent RNA copy number in clinical samples was calculated to 220 
estimate viral load (Figure 3). 221 
Besides HRSV, PCR was performed to detect influenza viruses (Flu), human 222 
metapneumovirus (hMPV), human rhinoviruses, (HRV), human enterovirus (HEV), 223 
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parainfluenza viruses (PIV) and adenovirus (AdV) as previously described 45. 224 
To detect bacteria in blood, 1ml of venous blood was collected aseptically and blood culture 225 
was performed as previously described in hospitalized patients 45. 226 
 227 
Statistical analysis 228 
Demographic characteristics and symptoms were compared. Chi-square test was used 229 
to compare the proportion. Student`s t-test, Mann-Whitney U test and Kruskal-Wallis test was 230 
used for continuous variables. All figures and graphs were generated using Prism software 231 
(version 6) (GraphPad software, San Diego, CA). Viral load converted from Ct values into 232 
RNA copies was compared among different genotypes. Generalized linear regression model 233 
(GLM) was used to evaluate association between Ct value and social or clinical factors such 234 
as: age, nutritional status, duration of symptoms, coinfection, difficulty to breathe and gender. 235 
All variables with P value of less than 0.1 in univariate analysis were put into the multivariate 236 
model. Significance tests were conducted with 2-tailed and P value < 0.05 was considered 237 
statistically significant. All statistical tests were performed using IBM SPSS Statistics for 238 
Windows, version 20 (IBM Corp, Armonk, NY, USA).  239 
240 
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 RESULTS 241 
 242 
Clinical characteristics of the study population 243 
A total of 441 clinical samples were collected from children between September 2012 244 
and December 2013, who were admitted due to severe acute respiratory infections. Of these, 245 
179 (40.6%) samples were positive for HRSV. There were three main HRSV genotypes 246 
including NA1 and ON1 in HRSV-A and BA9 in HRSV-B, which circulated in the study 247 
period (Figure 4a). The HRSV viral loads of 150 (83.8%) samples were measured and 248 
obtained from 146 (98.0%) samples by qPCR. Six samples were excluded because 4 samples 249 
were positive only in one of the duplicates. Two more samples were excluded due to negative 250 
result by PCR test for subgrouping. Moreover, only one sample of GB2 genotype identified 251 
was removed from the analysis of viral load association with genotypes. The mean of age was 252 
1.0 year, and the median age was 0.74 years (interquartile range IQR, 0.26-1.42) and 60.4% 253 
were males. All (140) enrolled patients had cough and running nose while 113 (80.7%) had 254 
fever and 104 (74.3%) had difficulty in breathing at admission. The clinical characteristics of 255 
140 patients are shown in Table 1. 256 
A total of 1,592 clinical samples from 1,499 subjects were collected in 2014 from all 257 
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three study sites including BPH (n = 361), RHU in Caibiran (n = 801), and RHU in Kawayan 258 
(n = 430). Of these, 106 (29.4%), 109 (13.6%), and 55 (12.8%) were positive to HRSV, 259 
respectively and HRSV positive rate of hospitalized patients was significantly higher than that 260 
of the RHU patients (P < 0.001). The monthly distributions of HRSV positive cases in three 261 
study sites were similar (Figure 4b). Blood culture test was negative in all hospitalized 262 
patients and co-infections with HRSV of other viruses (HRV, HEV, hMPV) were found in 24 263 
cases (8.9%). Altogether, initial diagnoses were 72 (26.7%) non-pneumonia, while 67 (24.8%) 264 
were pneumonia and 131 (48.5%) SP / VSP. Hospitalized patients were all diagnosed with SP 265 
/ VSP while patients who visited RHUs were clinically diagnosed mostly as non-pneumonia 266 
or pneumonia (P < 0.001). The demographic and clinical characteristics of 270 episodes from 267 
267 patients are shown in Table 2.  Hospitalized patients were younger than those who visited 268 
RHUs (P < .001). The percentage of male gender was similar in both hospital and RHUs (P = 269 
0.400). The duration of illness up to the NPS sampling was shorter (3 days) in patients from 270 
RHUs than hospital (P = .002). The educational level of female head was lower in 271 
hospitalized patients than those in RHUs (P < 0.001). The vaginal mode of delivery was 272 
92.9% for hospitalized patients and 100 % for RHUs patients (P = .001). Hospitalized 273 
patients had low weight at birth compare to those in RHUs (P < 0.001), but patients in RHUs 274 
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tended to be malnourished (P < 0.043). However, younger age and lower educational level 275 
tended to be associated with SP / VSP. Also lower weight at delivery was associated with 276 
SP / VSP (Supplementary table).  277 
 278 
Comparison of HRSV viral loads by subgroups and genotypes 279 
Viral load of patients infected with HRSV-A (n = 68) was slightly higher than HRSV 280 
subgroup B (n= 72) (P > 0.05) (Figure 5). HRSV loads were compared among the three main 281 
genotypes that were circulating during the study period. Genotype NA1 exhibited 282 
significantly higher viral load than ON1 and BA9 (P value < 0.001) (Figure 6A). In subjects 283 
aged less than 6 months, NA1 viral load was also higher than those of ON1 and BA9 (P < 284 
0.032) (Figure 6B). Moreover, In multiple regression analysis conducted to evaluate 285 
predictors of HRSV viral load including age, genotypes, symptom duration prior to sampling, 286 
co-infection and gender, showed that age at admission and genotypes were significant 287 
predictors of HRSV viral load (Table 3). 288 
Chest X-ray data were available for hospitalized patients and used for the analysis of 289 
association between HRSV viral load and presence of infiltrate on the X-ray radiographs. In 290 
139 hospitalized patients, 128 (92.1%) had X-ray data. Only 3 had consolidation and all 3 had 291 
 20 
both infiltration and consolidation. No difference was observed in viral load between the 292 
presence and absence of infiltration (P = 0.441). The proportion of the patients who had 293 
infiltration was smaller in the ones with NA1 than those with other genotypes (Table 1) 294 
and the difference was significant after adjusting for age in months (Odds ratio: 0.2, 295 
95%CI: 0.1-0.9). 296 
 297 
HRSV Ct value, pneumonia severity, duration of illness prior to sampling and patient 298 
facility 299 
HRSV Ct values by clinical diagnosis showed no difference among no pneumonia 300 
(NP), pneumonia (P) and SP / VSP without and with adjustment. Unexpectedly, the 301 
hospitalized children had higher Ct value indicating lower HRSV viral load in the NPS swab 302 
samples.  The regression line of HRSV Ct value was not associated with the duration of 303 
illness from the onset to NPS sampling in hospitalized patients (P < 0.429) (Table 4a) but 304 
was positively associated with RHU patients (P < 0.001) (Table 4b).  305 
There was a significant decrease of viral load (increased Ct value) with longer duration of 306 
illness prior to sampling with all children (P < 0.001) (Figure 7). But HRSV viral load was 307 
not associated with the duration of illness prior to sampling in hospitalized cases in 2013. 308 
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To check potential misclassification of HRSV positive patients due to decrease in 309 
sensitivity of diagnosis by delayed PCR testing, HRSV positive rates by duration of illness 310 
prior to sampling in three categories; 1-4, 5-8 and 9-14 days were analyzed in RHU and 311 
hospital patients in 2014. The data of duration of illness were available from 1528 312 
(95.8%) of the 1592 samples and the positive rates for 1-4, 5-8 and 9-14 days were 313 
0.174, 0.246 and 0.213, respectively, showing no significant decrease (P < 0.636) in 314 
positivity of HRSV by later diagnosis in the study population.  315 
Independent factors associated with HRSV Ct value were analyzed using multiple 316 
regression model (Table 4c).  The model predicts that having ≥ 4 days of duration of illness 317 
since onset increases of about 1.5 of the Ct value (decrease of HRSV viral load) compared to 318 
< 4 days. Also HRSV viral load in RHUs patients was unexpectedly higher than hospitalized 319 
patients (P < 0.012). Other factors found to be associated with HRSV Ct value in univariate 320 
analysis with a P value of at least < 0.1 were not confirmed as independent factors of HRSV 321 
Ct value (P < 0.05) such as pneumonia severity group based on IMCI guidelines, gender and 322 
difficulty to breathe and grunting. 323 
 324 
 325 
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 326 
DISCUSSIONS 327 
 328 
In previous studies, HRSV has been found as the most common etiology agent of acute 329 
LRTI in children the Philippines 45,46. Therefore, I conducted these studies to compare HRSV 330 
viral load among genotypes during a season in which more than two genotypes circulated, and 331 
also to investigate HRSV viral load association with clinical disease severity. Viral loads were 332 
higher in patients with genotype NA1 than in those with genotypes ON1 and BA9. Multiple 333 
regression analysis showed that younger age at admission and genotype NA1 were 334 
significantly associated with higher HRSV viral load. Because the NA1 viral load was also 335 
higher in infants less than 6 months of age, possibly their first HRSV infections, the 336 
immunological effects of prior infection was minimal. Since genotype NA1 had been a major 337 
genotype 43 and ON1 newly introduced in this area during the study period, the effect of 338 
maternal immunity does not explain the low viral load of ON1. Therefore, the difference of 339 
viral loads among genotypes was not likely due to differences in preexisting immunity at 340 
enrollment. In addition, previous studies have also shown that neutralizing antibody titer at 341 
disease onset is not associated with HRSV viral load 47. HRSV viral load showed a strong 342 
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positive correlation with younger age at admission. Young infants undergo significant 343 
anatomic and immunological changes during their development, which may affect HRSV 344 
replication patterns in different pediatric age groups. 345 
Genetic differences among genotypes may explain the differences in viral load. ON1 346 
has a 72-nucleotide insertion in the G gene 14. This insertion is absent in the NA1 genotype 347 
and is the largest insertion described to date in this genus, which may affect the viral structure 348 
and pathogenesis. BA9, also characterized by an insertion in the G gene, also showed 349 
significantly lower viral load compared to NA1. The G protein is one of the major HRSV 350 
protective antigens and has significant roles in viral attachment to cell surface 48, cell fusion 49, 351 
and immune response 50. Insertions and duplications in the G gene may affect the efficiency 352 
of HRSV replication in the newly emerged ON1 and BA genotypes. Although there has been 353 
no direct evidence regarding this association for HRSV to my knowledge. Detailed molecular 354 
analysis of the G protein gene sequence of several HRSV strains commonly reveal multiple 355 
short sequence repeats. The earlier report in HRSV-B of the 60-nucleotide duplication (the 356 
BA genotypes) had shown an example of repeated sequence in the G protein, which emerged 357 
and replaced previous genotypes within HRSV-B 16. However, it is unclear why ON1 is 358 
becoming a predominant strain and replacing NA1, if ON1 has a disadvantage in virus 359 
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replication. Further studies are needed to better understand why viral load differs among 360 
genotypes as well as the impact of new insertions in the G gene on HRSV viral replication 361 
and pathogenesis. Patients with HRSV NA1 tended not to have infiltration in chest x-ray 362 
compare to other genotypes. Infection of NA1 may have occurred relatively higher level of 363 
upper respiratory tract in this study population. 364 
There was no significant difference of viral loads between HRSV A and HRSV B in the 365 
first year (September 2012 to December 2013), when the three genotypes (NA1, ON1 and 366 
BA9) were co-circulating and also in the second year in 2014, when the two genotypes (ON1 367 
and BA9) were circulating. However in 2013, NA1 viral load was significantly higher than 368 
BA9, although there was no difference between ON1 and BA9. Lack of difference of viral 369 
load between subgroups may be due to the newly emerged ON1 with lower viral load than 370 
NA1 in HRSV-A. The viral load measurement by qPCR is proportional to production of viral 371 
particles 55. And techniques such as plaque assay would not titrate all viral particles in 372 
inoculum or within infected cells. Although other studies using molecular techniques did not 373 
find difference in viral load between HRSV subgroups 42,56 the reason could be likely due to 374 
sample size, variation in samples collection or circulating genotypes. Circulating genotypes 375 
may indirectly have an important effect on HRSV viral load association with disease severity. 376 
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In 2014, the proportion of HRSV in the hospitalized patients with SP / VSP was more than 377 
twice as much as that in RHUs where most of the children with LRTI had non-severe disease, 378 
suggesting that HRSV is associated with severe pneumonia in children compared with other 379 
viruses. Using criteria of the severity of disease based on the IMCI guidelines or other 380 
potential clinical indicators, I did not find the severity of clinical disease association with 381 
HRSV viral load. Although, small sample size of patients with danger signs i.e. very severe 382 
cases might have affected on some variables, the viral factors did not seem to have potential 383 
association with severity of the disease. 384 
Several studies have compared viral load of HRSV among children with different levels of 385 
severity in the hospital settings. The association of HRSV viral load with disease severity has 386 
been somehow controversial among previous studies. Several studies found association of 387 
HRSV viral load estimated by cell culture and molecular methods with disease severity 6,29-34 388 
whereas other did not confirm such association 47,57,58 (Table 5). Most of the studies were 389 
conducted in the countries where intensive care unit or proper respiratory management were 390 
available, therefore hospitalization, duration of hospitalization and intensive care requirement 391 
could be used as the outcome measurement. The quality of medical care, availability of 392 
relevant facilities or health insurance policy might have affected the conclusions 59. In 393 
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contrast, in settings where the resources are limited, evaluation of the severity of respiratory 394 
disease is challenging. Criteria for hospital admission and discharge or intensive care 395 
requirement vary across facilities and severity indexes or indicators may not always be 396 
adequate to replicate the study. Two studies in which one used severity markers including 397 
non-severe control and outpatient 34 and the other used severity markers including all 398 
hospitalized cases 31 both from developing countries found association of HRSV viral load 399 
with disease severity. But this association was not consistent in all age groups under five  400 
years 34. I used NPS while previous studies used nasal aspirate, nasal wash (NW) or 401 
nasopharyngeal aspirate (NPA). Nasopharynx is identified as the optimal sampling site for 402 
HRSV detection 60. NPA specimens were shown to have higher viral titer than NPS specimen 403 
in HRSV viral quantification studies 60,61. But these previous findings remained to be 404 
confirmed for HRSV molecular quantification as shown with other virus such as influenza for 405 
which NPA specimen is better than NS or throat swab (TS) 62. Therefore, the type of 406 
specimens used for quantification may also affect HRSV viral load and its association with 407 
disease severity.  408 
 Distinctly, my study is most recent including the newly emerged ON1 genotype in HRSV 409 
A subgroup. The severity of HRSV infection may be related to circulating viral strains 63. The 410 
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genotypes of circulating strains in 2013 were identified as potential predictors of HRSV viral 411 
load and the non-association of HRSV viral load with disease severity may be also due to 412 
current circulating strains with newly emerged genotype.  413 
The criteria for pneumonia and severe pneumonia used by IMCI are based on the 414 
objective to recognize the clinical signs and give oral/injectable antibiotics for bacterial 415 
pneumonia. In RHUs, HRSV viral load was higher in the severe cases by IMCI criteria 416 
without statistical significance, which may be due to the small samples size of the severe 417 
cases, but in the hospital cases, HRSV viral load was not associated with the danger signs 418 
defined by IMCI, such as inability to drink, wheezing of those considered as severity index 419 
for HRSV infection.  420 
Besides viral load, the severity of HRSV disease may also be explained by host-related 421 
factors rather than viral factors. Early studies postulated the pathogenesis of HRSV disease to 422 
be due to host immune response 64-66, the formation of immune complex 67 or potential 423 
inappropriate shift toward a Th2 from a Th1 response in cell-mediated immune responses 68.  424 
Recent studies also showed a plausibility of association of immunogenetic factors with HRSV 425 
disease severity 69-74. For example Olfactomedin4 (OLFM4) gene expression level in 426 
peripheral blood mononuclear cell (PBMC) is associated with the severity of the disease in 427 
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children with HRSV LRTI 74. The relationship between HRSV viral load and disease severity 428 
remains a complex issue, which may be affected by host and viral factors.  429 
HRSV viral load was found to be associated with the number of days of illness prior to 430 
sampling in the second year 2014, but not in 2013 which included smaller sample size. This 431 
finding may infer that HRSV viral load is affected by the number of duration of illness prior 432 
to sample collection in patients with severe LRTI. Previous studies has found significant 433 
decrease of viral load with the increased of duration of illness prior to admission in children 434 
younger than 2 years 6. And I found this association in children aged less than 5 years.  435 
There was a difference of HRSV viral load between facilities. RHUs patients had higher 436 
HRSV viral load than hospital patients, which was an unexpected inverse association between 437 
HRSV viral loads since the hospital cases with severe disease were expected to have higher 438 
viral load than those in RHUs. The association stayed significant even after adjustment by 439 
other potential variables (such as age, sex and duration of illness prior to sampling). 440 
Difference in HRSV viral load between facilities could be explained by variance such as the 441 
techniques used in sample collection at different facilities though to minimize such 442 
differences and poor-quality sample, study personnel were trained with lecture, hands-on 443 
practices and written instructions following a standardized protocol. The difference could be 444 
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explained by unequal volume of swab during sampling. It is more difficult to take clinical 445 
samples from younger infants or toddlers than older children75 . Hospitalized patients were 446 
younger than patients in RHUs (P < .001). The amount of swab samples from patients in 447 
RHUs might have been larger than those from hospitalized infants which may explain higher 448 
viral load in RHUs patients. The Ct value in RHUs was significantly affected by the timing of 449 
the sampling. Patients in RHUs tend to have shorter duration of illness prior to visit compare 450 
to hospitalized patients (P = .002), which is similar to the outpatient in Kenyan study 34. 451 
The education level of the female head was found associated with the severity of the 452 
disease i.e. hospitalized cases but this was not found in RHUs patients. Children of female 453 
head with low education level (elementary) tend to have SP / VSP while children of female 454 
head with high education level (high school or more) tend to have non-pneumonia or 455 
pneumonia. Among parents, mothers with high education level are prone for appropriate and 456 
early consultation for illness in their children 76.   457 
This study had several limitations. Firstly, the two studies were conducted only in one 458 
HRSV season each; therefore studies with multiple seasons and sites will confirm these 459 
findings. Secondly, the measurement of viral load by molecular techniques may not precisely 460 
indicate replication of etiological virus associated to clinical symptoms. The isolation of virus 461 
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and replication in cell culture were not included in this study. Thirdly, the severity of acute 462 
lower respiratory infection may not be fully attributed to HRSV alone, especially in the case 463 
of having bacterial co-infection, which could be underestimated due to low sensitivity in 464 
blood culture77. Despite these limitations, this is the first study on potential association of 465 
HRSV viral load with different genotypes and relationship of HRSV viral load with childhood 466 
pneumonia and current findings would contribute to the understanding of genotypes and 467 
HRSV viral load association with disease severity. In the present study, age and genotypes 468 
independently predicted HRSV viral load. Age is a well-known predictor in HRSV disease 469 
severity 78 and also can predict HRSV viral load. Also genotype may potentially predict 470 
HRSV viral load, but no association could be found between HRSV viral load and clinical 471 
disease severity.  472 
 473 
474 
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IV.  CONCLUSION 475 
My study investigated the potential difference of viral load between HRSV genotypes and 476 
association of HRSV viral load with disease severity. NA1 viral load was higher than the 477 
closely related newly emerged ON1 within HRSV-A and BA9 in HRSV-B in the first year in 478 
which mainly three genotypes circulated in the Island. I found besides age that genotype was 479 
a potential predictor of HRSV viral load. Further investigation in multiple seasons is needed 480 
to define the impact of circulating genotypes on HRSV viral load. Also, the second year, 481 
which included non-severe cases, showed no association of HRSV viral load with clinical 482 
disease severity after adjustment with potential confounders. Meanwhile the duration of 483 
illness and patient facility were found as important explanatory variables of HRSV viral load. 484 
It is the first study on HRSV virus load association and direct clinical disease diagnosis. 485 
Further study should be required to confirm the present finding. 486 
 487 
488 
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VI. TABLES 714 
 715 
 
Table 1. Characteristics of 139 hospitalized patients due to severe acute respiratory infection 
by HRSV genotypes. 
 
HRSV genotype NA1 ON1 BA9 P value 
 n =17 n =51 n =71  
Age in months, median [IQR] 10 [3–19] 6 [3–11] 11 [5–19] 0.026a 
Days between illness onset and specimen 
collection, median [IQR] 4 [3–5] 5 [4–7] 4 [3–7] 0.074
a 
  
Males (%) 10 (58.8) 33 (64.7) 41 (57.7) 0.733b 
Symptoms (%)     
   Fever 13 (76.5) 39 (76.5) 61 (85.9) 0.361b 
   Runny nose 17 (100.0) 51 (100.0) 71 (100.0) - 
   Cough 17 (100.0) 51 (100.0) 71 (100.0) - 
   Breathing difficulty  12 (70.6) 41 (80.4) 50 (70.4) 0.436b 
Viral coinfection (%) 0 (0.0) 7 (13.7) 4 (8.4) 0.114b 
     
Log10RNA copies/μL, median [IQR]  
   All ages  5.3 [4.6–5.6] 4.2 [3.4–5.0] 4.1 [3.6–4.9] < 0.001c 
< 6 months 
n=6 n=27 n=21  
5.4 [5.0–6.0]  4.5 [3.5–5.2] 4.6 [4.0–5.0] 0.032a 
Chest x-ray infiltration, Yes (%) 3(20.0) 22(46.8) 34(52.3) 0.077b 
 716 
a: Kruskal-Wallis test, b: chi-square test, c: one-way ANOVA.  717 
       HRSV: Human Respiratory Syncytial Virus, IQR: 25th and 75th Interquartile range. 718
 One patient identified with GB2 genotype was excluded from this analysis. Chest x-ray data was 719 
available from 128 patients including one patient with HRSV GB2. 720 
721 
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 722 
Table 2. Characteristics of study population of children with respiratory symptom and RSV    723 
infection in Biliran Island, Philippines in 2014. 724 
 Descriptors / Symptoms 
Hospital 
(BPH) 
 
 
Health  
Post 1 
(RHU) 
 
Health  
Post 2 
(RHU) 
 
P-
value  
RHU
1 Vs.  
RHU
2 
P-value 
BPH  
Vs.  
RHUs 
 n=106 n =109 n =55   
Age in months 8.4[3.6-14.4] 15.6[8.4-26.4] 16.8[9.6-33.6] .400a < .001a 
# Male (%) 52(49.1) 60(55.0) 29(52.7) .900b .400b 
# days from onset of illness to sampling, median[IQR] 4.0[3.0-5.0] 4.0[3.0-5.0] 3.0[2.0-5.0] .200a .002a 
Clinical symptoms      
Difficulty to breathe (%) 62.3 18.3 14.5 .700b < .001b 
Fever (%) 67.0 70.6 74.5 .700b .400b 
Cough (%) 100.0 99.1 100 1.00b 1.00b 
Inability to drink (%) 12.3 0.0 5.4 .030b .001b 
Wheezing (%)  11.3 32.1 14.5 .023b < .003b 
Grunting (%)  0.0 1.9 21.8 < .001b < .002b 
Chest indrawing (%) 100.0 11.0 16.4 .300b < .001b 
Central cyanosis (%) 0.00 0.0 0.0 1.00b 1.00b 
Convulsion (%) 1.90 2.7 0.0 .500b 1.000b 
# SpO2 level reportedc 29 102 50   
SpO2 < 90(%)c (10.3) 11.8 0.0 - .700b 
# Mode of delivery reported 99 101 52 - - 
Vaginal, (%)       92.9 100 100 1.00b .001b 
Weight at delivery, median [IQR] 2.8[2.5-3.2] 3.1[2.7-3.3] 2.9[2.6–3.1] .242a < .001a 
#Breastfeeding < 6mos reported 42 21 8 - - 
Yes (%) 100 100 100 1.00b 1.000b 
# Education level female head/spouse 99 106 55 - - 
Elementary (%) 77.8 16.0 29.1 
.029b 
 
< .001b 
 
High school (%) 22.2 60.4 61.8 
Vocational/College (%) 0.00 23.6 9.1 
Z-score for height for age (%)      
Obesity (> 2) 9.4 7.3 1.8 .274b .233 
      Adequate (>–2 to < 2) 76.4 79.8 53.7 .001b .398 
Malnutrition (–> 3 to < –2) 5.7 6.4 29.6 < .001b .043 
Severe Malnutrition (<–3) 8.5 6.4 14.8 .091b 1.000 
# HRSV Subgroups/Genotyped 105 101 53   
HRSV-A, ON1 (%) 75.2 78.2 67.9 .117 1.000 
HRSV-B/ BA9 (%) 24.8 21.8 32.1 .177 1.000 
Coinfection 7.5 10.1 9.1 1.000 .663 
 725 
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BPH: Biliran provincial hospital, RHU: Rural health unit, HRSV: Human respiratory 726 
syncytial virus. Otherwise stated, [IQR]: Interquartile range (25th-75th).                            727 
 a : Mann-Whitney U-test, b : Chi-Square test,  c : SpO2 measured before bronchotherapy 728 
 729 
730 
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 731 
Table 3. Distribution of factors and coefficients by GML for HRSV viral load.  732 
 733 
HRSV: human respiratory syncytial virus, Ct: cycle threshold. β: Coefficients were adjusted 734 
for each other by generalized linear model and can be interpreted as the slope indicating the 735 
change in dependent variable per unit change in independent variable 736 
One patient positive for genotype GB2 was excluded from this analysis. 737 
GML: Generalized linear model 738 
 739 
740 
Variables Categories n β (95% CI) P value 
Age (months) 
< 6 54 
Ref. 
- 
6–11.9 32 
−0.21 (−0.57 - 0.15) 0.264 
≥ 12 53 
−0.55 (−0.92 - −0.18) 0.004 
Sex 
Female 55 Ref. - 
Male 84 0.28 (−0.02 - 0.58) 0.072 
Days between illness onset and specimen collection 
< 4 45 Ref. - 
≥ 4 94 0.15 (−0.16 - 0.46) 0.347 
Genotype 
NA1 17 Ref. - 
ON1 51 −1.13 (−1.53 - −0.73) < 0.001 
BA9 71 −0.92 (−1.27 - −0.56) < 0.001 
Viral coinfection 
No 128 Ref. - 
Yes 11 −0.19 (−0.82 - 0.44) 0.552 
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Table 4a. Association between real-time PCR Ct value of RSV and clinical characteristics  
of hospitalized patients with acute respiratory illness in 2014 
 
Setting: Hospital Categories n Univariate Multivariate 
Variables   β (95% CI) P value β (95% CI) P value 
Age (Months) 
< 6 43 Ref -   
6-11.9 25 .18(-1.49–1.85) .834   
12-23.9 38 .15(-1.92–1.16) .627   
Duration of illness prior to  
sample collection (days) 
< 4  29 Ref -   
≥ 4 77 .60(-.94−2.15) .443   
Viral coinfection no 98 Ref -   yes 8 -1.91(-3.64−-.18) .030 -1.81(-3.37−.-.25) .023 
Sex Female 54 Ref -   Male 52 1.14(-.17−2.45) .088 .86(-.41−2.13) .186 
Fever no 35 Ref -   yes 71 -.51(-1.89−.87) .471   
Cough no 0 -    yes 106 -    
Difficulty to breathe no 40 Ref -  - yes 66 1.72(.39−3.06) .011 1.6(.30−2.90) .016 
Wheezing no 94 Ref -   yes 12 .-15(-1.96−2.23) .890   
Grunting no 106     yes 0     
Inability to drink no 16 Ref -   yes 254 1.42(-.49−3.33) .146   
SpO2 level 
< 90 3 Ref -   
≥ 90 26 1.24(-1.52−4.01) .377   
Pneumonia severity 
(Based on IMCI guidelines) 
Non pneumonia 0     
Pneumonia 0     
SP/VSP 106     
RSV subgroups  A 79 Ref -    B 26 -1.04(-2.67−.60) .214   
Nutritional status 
Adequate 72 Ref -   
Malnourished 6 1.44(-1.12−4.00) .270   
Severely malnourished 9 .52(-2.14−3.34) .667   
 
SP/VSP: Severe pneumonia or very severe pneumonia according to the IMCI criteria 
Multivariate regression model is used to determine the association of RSV Ct value with pneumonia 
severity controlling with potential confounders. 
β: Coefficient of regression 
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Table 4b. Association between real-time PCR Ct value of RSV and clinical characteristics of 
rural health units (RHUs) patients with acute respiratory illness in 2014 
Settings: RHUs Categories n Univariate Multivariate 
Variables   β (95% CI) P value β (95% CI) P value 
Age (Months) 
< 6 31 Ref -   
6-11.9 25 -2.59(-4.55–-.64) .009 -2.49(-4.36–-.64) .008 
≥ 12 108 -.68(-2.41–1.05) .442 -.47(-2.18–1.24) .586 
Duration of illness prior to  
sample collection (days) 
< 4  80 Ref -   
≥ 4 84 2.07(.82–3.31)  .001 2.19(1.00–3.38)  < .001 
Viral coinfection 
no 148 Ref -   
yes 16 -.01(-1.80–1.78) .989   
Sex 
Female 75 Ref -   
Male 89 .94(−.34–2.22) .149   
Fever no 46 Ref -   
yes 118 -.21(-1.68–1.27) .785   
Cough no 1     yes 163     
Difficulty to breathe 
no 136 Ref -   
yes 28 -.46(-2.12–1.19) .584   
Wheezing 
no 121 Ref -   
yes 43 .22(-1.22–.1.67) .763   
Grunting 
no 150 Ref -   
yes 14 −1.05(-3.06–.96) .308   
SpO2 level 
< 90 12 Ref -   
≥ 90 140 -.54(-3.31–2.22) .700   
Pneumonia severity 
(Based on IMCI guidelines) 
Non pneumonia 72 Ref -   
Pneumonia 67 -.66(-2.06–.74) .354   
SP/VSP 25 -46(-2.27–1.35) .620   
RSV subgroups 
 A 115 Ref -   
 B 39 -.47(-1.74–.80) .472   
Nutritional status 
Adequate+Obese 106 Ref -   
Malnourished 23 -1.64(-3.39–.12) .068 -1.56(-3.31–.22)  .086 
Severely 
malnourished 15 .61(-1.37–2.58) .548 .75(-1.20–2.70)  .451 
 
SP/VSP: Severe pneumonia or very severe pneumonia according to the IMCI criteria 
Multivariate regression model is used to determine the association of RSV Ct value with 
pneumonia severity controlling with potential confounders. 
β: Coefficient of regression 
 744 
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Table 4c. Association between real-time PCR Ct value of RSV and clinical characteristics in 
patients with acute respiratory illness in 2014 
Variables Categories n 
 
              Univariate                     Multivariate  
  β (95% CI) P value β (95% CI) P value 
Age (Months) 
< 6 74 Ref − − − 
6-11.9 50 .89(−-85–2.63) .317   
≥ 12 146 .15(-1.52–1.82) .861   
Duration of illness prior to  
sample collection (days) 
< 4 109 Ref − − − 
≥ 4 161 1.98 (1.01−2.94) < .001 1.54(.56–2.52) .002 
Facility RHUs 164 Ref − −  
Hospital 106 2.22 (1.30−3.15) < .001 2.04(.44−3.63) .012 
Viral coinfection No 246 Ref −   
Yes 24 -.80 (-2.51−.91) .358   
Sex Female 129 Ref − − − 
Male 141 .90(−.06−1.87) .067 .89 (-.02–1.82) .056 
Fever No 81 Ref −   
Yes 189 -.45(-1.51−.61) .402   
Cough no 1 -    
yes 269 -    
Difficulty to breathe No 176 Ref − − − 
Yes 94 1.59 (.59−2.59) .002 .50(-.56–1.57) .353 
Wheezing No 215 Ref −   
Yes 55 . −29(-1.50−.91) .632   
Grunting No 256 Ref  − − 
Yes 14 -1.94 (-4.12−.24) .081 -.24 (-2.07−1.59) .797 
SpO2 level < 90% 15 Ref −   
≥ 90% 166 .81 (-.80−2.43) .323   
Pneumonia severity 
(Based on IMCI guidelines) 
Non pneumonia 72 Ref − − − 
Pneumonia 67 -.66 (-1.98−.67) .331 -1.03 (-2.38−.32) .135 
SP/VSP 131 1.46 (.32−2.61) .012 -.99(-2.74–.76) .267 
RSV subgroups A 195 Ref −   
B 65 -.71 (-1.85−.42) .216   
Nutritional status Adequate 197 Ref − − − 
Malnourished 29 −1.41 (-3.05−.23) .091 -.98(-2.49−.56) .215 
Severely malnourished 24 .52(-1.13−2.16) .540 .42(-1.13−1.98) .593 
 
SP/VSP: Severe pneumonia or very severe pneumonia according to the IMCI criteria 
Multivariate regression model is used to determine the association of RSV Ct value with pneumonia 
severity controlling with potential confounders. 
β: Coefficient of regression.   
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746 Table 5. Studies on RSV viral load and disease severity 
 
Study Country Study period 
Age 
(Years) 
Sample 
size 
(RSV) 
Clinical 
sample Laboratory test Clinical diagnosis Setting Severity markers RSV titer unit Ref 
1 USA - < 2 39 NA Plaque assay - Hospital Mechanical ventilation (PFU/ml) [29]* 
2 USA 1997-2001 < 2 141 NW Plaque assay - Hospital 
Duration of hospitalization, ICU required, Respiratory 
failure (PFU/ml) [6]* 
3 USA - < 2 219 NA Plaque assay - Hospital Hospitalization, Duration of hospitalization, ICU required, Respiratory failure  (PFU/ml) [34]* 
4 Netherlands 2006-2008 < 0.5 82 NPA Real-time PCR - Hospital Severity scores based on clinical symptoms
a Ct value [33]* 
5 Tunisia 2005 ≤ 1 81 NPA Real-time PCR Bronchiolitis Hospital Respiratory rate, duration of hospitalization, ICU required or mechanical ventilation 
 
(Transcripts/ml) 
 
[30]* 
5 Kenya 2008-2010 < 5 370 N/OPA Real-time PCR 
Afebrile, ILI, 
SARD Hospital Control, Outpatients, Inpatients Ct value [32]* 
7 USA, Finland 
2007-
2010 < 2 1764 NPA Real-time PCR Bronchiolitis Hospital 
Length of hospital stay ≥ 3 days, Intensive care use 
(admission and/or use of mechanical ventilation) Ct value [31]* 
8 USA 1990- 1994 ≤ 2 77 NW Plaque assay Bronchiolitis Hospital 
Sum of illness scores for up 13 days after enrollment 
(length of time for supplemental oxygen and ventilator 
support) 
(PFU/ml) [47] 
9 Netherlands 2006-2007 < 6 48 NPA Multiplex PCR ARTI Hospital 
Mild illness and severe illness (Respiratory rate, O-sat≤ 
92, retractions, nasal flaring, mechanical ventilation) Cp value [53] 
10 Germany 2006-2008 ≤ 16 160 NPA Real-time PCR 
Pneumonia, 
wheezing Hospital 
Duration of hospitalization, supplemental oxygen 
required, use of bronchodilators, systemic corticosteroids, 
use of antibiotics, chest radiography and presence of fever 
 (Copies/ml) [54] 
11 This study 2014 < 5 270 NPS Real-time PCR ARTI Hospital RHUs Non pneumonia, pneumonia and SP/VSP Ct value -- 
 
*: Study reporting on significant RSV viral load association with disease severity NA: Nasal aspirate, NW: Nasal wash, N/OPA: Nasal or oropharyngeal 
aspirate, NPA: Nasopharyngeal aspirate, NPS: Nasopharyngeal swab, TA: Tracheal aspirate. ILI: Influenza like illness, SARD: Severe acute respiratory 
disease a: Fever, cough, rhinorrhea, hoarseness, duration of illness, apnea, wheezing, cyanosis, retractions, tachypnea. PFU: Plaque forming unit, Ct: Cycle 
threshold, Cp: Crossing point ARTI: Acute respiratory tract infection. RHUs: Rural health units, SP/VSP: Severe pneumonia or very severe pneumonia. 
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Supplementary table: Risk factors associated with HRSV disease severity in 747 
Descriptors/ 
Symptoms 
Non pneumonia 
Total= 72 
Pneumonia 
Total= 67 
Severe or very severe 
Pneumonia 
Total= 131 
P value 
Age, median months  20.5[8.1-34.7] 15.4[9.0-23.2] 9.5[4.1-14.8] <. 001a 
Sex Male (%) 44.4 68.8 51.1 .093 b 
Weight at delivery, #(%) 56(77.8) 49(73.1) 99(75.6)  
Median of weight (Kg) median [IQR] 3.1[2.8-3.3] 2.9[2.7-3.2] 2.8[2.5-3.2] < .045a 
Being Breastfed<6months, #, (%) 14(19.4) 13(19.4) 44(33.6)  
Yes (%) 92.8 100.0 93.2 .621 b 
Education level of female head/spouse, #, (%) 70(97.2) 66(98.5) 124(94.6)  
Elementary (%) 17.1 19.7 68.5 <. 001 b 
High school (%) 62.8 62.1 28.2 <. 001 b 
Vocational/College (%) 20.0 18.2 3.2 <. 001 b 
Z-score Malnutrition† *(%)     
Adequate 77.6 86.7 79.0 .719 b 
Moderately malnourished 12.9 0.0 11.8 .338 b 
Severely malnourished 9.5 13.3 9.2 .878 b 
 
Otherwise stated, Age and the duration of illness are given as median with the 25th and 75th percentile 
in segments. 
Duration of illness is defines as the earliest onset within 14 days of any of the clinical symptoms which 
include cough, fever and difficulty to breathe obtained by interview with the guardians.  
[IQR]: Interquartile range (25th-75th). 
a: Kruskal-Wallis Test. b: Chi-Square Tests. HRSV: Human respiratory syncytial virus 
†: The WHO anthropometric calculator was used for the assessment of malnutrition status of subjects 
and classified as adequate (-2< Z-score<+2), moderately malnourished (-3< Z-score<-2) and severely 
malnourished (Z-score <-3).  
*: 1 patient z score for nutrition in the non-pneumonia group was undetermined and others (19 cases) 
had a z score > 2 
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patients with acute respiratory illness. 748 
VII. Figures 749 
 750 
 751 
Figure 1. Schematic representation of HRSV genome based on Genbank accession no. 752 
NC_001781 753 
 754 
 
LEGEND 
NS: Non structural proteins  
N: Nucleoprotein  
P: Phosphoprotein 
M: Matrix protein 
SH: Small hydrophobic protein  
G: Glycoprotein 
F: Fusion protein 
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764 
M2: Matrix protein 
L: Large protein 
 57 
 765 
 766 
 767 
Figure 2. Study sites: Biliran Province, the Eastern Visayas Region 768 
(Region VIII), the Philippines. (Modified from Kosai, et al,  PlosOne 2015) 769 
 770 
RHUs: Rural health units. BPH: Biliran provincial hospital 771 
 772 
 773 
 774 
 775 
 776 
 777 
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 778 
 779 
 780 
Figure 3. Quantitative PCR amplification of partial sequence (658 nucleotides) of N 781 
genes of HRSV NA1, ON1 and BA9 genotypes.  782 
 783 
A dilution series of high-quality RNA copies was used to generate standard curves as describe 784 
in the methods. Reactions were performed in triplicate. HRSV genotypes Ct values stand for 785 
the cycle at which reporter fluorescence crosses the software-defined threshold. The linear 786 
range of threshold cycle vs RNA copies was (2 - 9) Log10 copies/μL. Solid line, linear 787 
regression of RNA copies vs Ct values. Dashed lines represent the 95% confidence intervals 788 
for potential regression lines. The slopes and y-intercepts are -3.70, 43.40 for NA1, -3.77, 789 
43.87 for ON1 and -3.74, 43.95 for BA9. 790 
HRSV: Human respiratory syncytial virus 791 
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 794 
Figure 4a. HRSV case distribution by genotypes in patients hospitalized 795 
due to severe acute respiratory illness (Sep 2012 – Dec 2013. 796 
  797 
HRSV: Human respiratory syncytial virus 798 
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Figure 4b. Distribution of HRSV positive cases with acute respiratory 810 
illness by study sites (Jan – Dec-2014). 811 
 812 
HRSV: Human respiratory syncytial virus 813 
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 817 
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 820 
 821 
 822 
 823 
Figure 5. Comparison of the HRSV viral load (RNA copies/μL)) between 824 
subgroups A and B. (Sept 2012– Dec 2013 825 
 826 
The means of viral load for HRSV-A and HRSV-B subgroups ± SD are 4.41 Log10 RNA 827 
copies/μL ± 0.99 and 4.21 Log10 RNA copies/μL ± 0.98, respectively.  828 
 62 
HRSV: Human respiratory syncytial virus 829 
 830 
831 
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 832 
 833 
 834 
Figure 6A. Comparison of viral load (RNA copies/μL) among different HRSV genotypes 835 
(Sept 2012 – Dec 2013). 836 
 837 
The Log10 RNA copies/μL means values ± SD for NA1, ON1 and BA9 genotypes are 5.16 ± 838 
0.66, 4.16 ± 0.95 and 4.23 ± 0.98 respectively.  839 
HRSV: Human respiratory syncytial virus 840 
 841 
 842 
 843 
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 844 
 845 
 846 
Figure 6B. Viral load (RNA copies/μL) differences among NA1, ON1 and BA9 genotypes 847 
in age groups less than 6 months (Sept 2012 – Dec 2013). 848 
 849 
 850 
The Log10 RNA copies means values ± SD for NA1 (n=6), ON1 (n=27) and BA9 (n=21) 851 
genotypes are 5.45 ± 0.67, 4.30 ± 0.97 and 4.57 ± 0.90 respectively. 852 
 853 
 854 
 855 
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 856 
 857 
 858 
Figure 7. Increase of HRSV Ct value with increase of duration of illness prior to 859 
sampling.  860 
 861 
The coefficient of the regression line is 0.343, 95% CI (0.162 - 0.524) and significantly 862 
different from zero; (R2= 0.050, P< .001). Dashed lines represent the 95% confidence 863 
intervals for potential regression lines. 864 
HRSV: Human respiratory syncytial virus 865 
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